NEW MEMBER SIGN UP
  Display Name
 
  Email Address
 
  Password
 
  Password again
 
  Zip
 
Country
 
   

Close Window

Privacy Statement
BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
     
Community Login

What is this?
Biotechnology and Pharmaceutical ChannelMedical Device and Diagnostics ChannelClinical Research Channel Employers
 Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My eNewsletters

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

COMMUNITY
Login
Become a Member
Discussion Forums
FAQ

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

BIOTECH WORK PORTAL
Career Definitions
Labor Market Reports
Education & Training
Regions

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

  News | News By Subject | News by Disease News By Date | Search News
   

National Institutes of Health (NIH) - Sponsored Macrolide Azithromycin COPD Phase III Study Utilizes Med-ic(R) Smart Blister Packaging
12/6/2005

OTTAWA, Dec. 6 /PRNewswire/ - Information Mediary Corporation has begun to supply over 30,000 of its Med-ic(R) RFID smart sensor labels for use in a large multi-year COPD Macrolide study. The study, sponsored by NIH's National Heart, Lung, and Blood Institute (NHLBI) will be enrolling over 1100 patients with moderate-to-severe chronic obstructive pulmonary disease (COPD), with emphasis on the prevention and management of exacerbations of the disease.

"With 17 study sites managed by 10 universities throughout the United States, the Med-ic ECM smart pharmaceutical blister technology (www.med-ic.biz) allows for immediate intervention upon patient visits, while the recorded adherence data will be an invaluable information source during the biostatistical evaluation of the trials outcome involving nearly half a million individual doses of medication" states Prof. Allan Wilson, MD, PhD, President of smart packaging experts Information Mediary Corp.

About Med-ic(R):

The Med-ic ECM (Electronic Compliance Monitor) is a revolutionary RFID sensor device that provides a disposable, inexpensive, state-of-the-art method to address the multi-billion dollar health care problem of medication non- compliance. Med-ic's unique patent-pending design makes it very easy to integrate and supply in large volumes at a reasonable unit cost.

Using intelligent technologies and advanced engineering, Information Mediary Corp. developed the Med-ic ECM to track medication usage for any standard blister packaging format without active patient input. The Med-ic ECM solution uses patent-pending sensor grid technology and a proprietary process of printed conductive inks from XINK Laboratories Ltd. (www.xink.biz) to form a smart paper label inlay.

The Med-ic CertiScan(R) RF Reader and CertiScan Compliance Monitoring Software (www.certiscan.biz) retrieve and display patient compliance information using the latest in RFID technology.

Study Background:

This Macrolide Azithromycin COPD Phase III study is currently enrolling patients at Denver City-County Health/Hospitals Department; University of Alabama, Birmingham; Harbor-UCLA Research & Education Institute; University of Minnesota Twin Cities; Temple University; University of California at San Francisco; University of Michigan; Minnesota Veterans Research Institute; Brigham and Women's Hospital; University of Maryland; and University of Pittsburgh.

Chronic obstructive pulmonary disease (COPD) is a serious public health problem that is responsible for more than 500,000 hospitalizations, 100,000 deaths, and $15 billion in direct costs of medical care in the U.S. each year. In addition, millions of Americans are disabled by this disease. While smoking cessation is of clear benefit in slowing the progressive loss of lung function that is characteristic of COPD, management of established disease is largely limited to supportive measures that do not interfere with the disease process itself. More effective management strategies are needed. There is particular need for better prevention and management of exacerbations of COPD since these are associated with a substantial portion of the hospitalizations, deaths, and costs of care attributable to the disease. While certain supportive measures (such as long term oxygen therapy) are of established benefit in selected patients, there remains considerable uncertainty regarding the effectiveness of many treatment modalities that are routinely used in COPD, indications for specific therapies, the usefulness of novel therapeutic approaches, and the best means for management of common comorbid conditions.

About Information Mediary Corporation:

Information Mediary Corporation offers custom designed RFID sensors (Class 3 EPC RFID tags), RFID readers, and groundbreaking innovations in printed electronics. IMC has developed affordable, low cost wireless cold chain temperature sensors, and smart label inlays that can monitor patient adherence with prescribed medication dispensed from intelligent pharmaceutical packages. For a detailed presentation about this technology, please refer to IMC's Intelligent Active Consumer Packaging Presentation.

INFORMATION MEDIARY CORP.

CONTACT: James Neilson, Med-ic Product Manager, (613) 745-8400 ext 411,jneilson@med-ic.biz; Joanne Watters, Med-ic Research and SupportSpecialist, (613) 745-8400 ext 404, jwatters@med-ic.biz



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES